Drugmaker Biohaven Pharmaceutical said on December 6 the company’s intranasal spray to treat migraine showed rapid pain relief and met the main goals in a late-stage study.
Europe crossed 75 million coronavirus cases on December 3, according to a Reuters tally, as the region braces for the new Omicron variant at a time when hospitals in some countries are already strained by the current surge.
Almost one year after Biogen forged a collaboration with Sage Therapeutics worth $1.52 billion, the development deal for the experimental major depressive disorder treatment zuranolone is bearing fruit that will support an expected rolling New Drug Application during 2022.
The U.S. Food and Drug Administration said on November 30 the regulatory agency was evaluating the effectiveness of authorized Covid-19 vaccines against the Omicron coronavirus variant and expects to have more information in the next few weeks.
One day after Bay Area-based Olema Pharmaceuticals announced that falsified information regarding its Phase I/II breast cancer data was circulating across the Internet, the company released topline data for OP-1250, a potential best-in-class complete estrogen receptor antagonist (CERAN).
Merck & Co. Inc.’s experimental Covid-19 drug molnupiravir should have similar activity against any new coronavirus variant, a company executive said on NOvember 30.
The latest data from Merck and Ridgeback Biotherapeutics’ MOVe-OUT trial on the use of molnupiravir to treat COVID-19 in adults has shown a lower efficacy than previously reported.
Amgen announced that the company’s Aimovig (erenumab-aooe) more than held the approved therapy’s ground against one of the most commonly prescribed migraine medications.
The popularity of decentralized clinical trials (DCTs) is surging, especially among patients. Harnessing technology of all kinds, these trials provide an attractive alternative to the old-style, site-anchored system on which traditional clinical trials have rested. They also have the potential to provide better, more timely data since that data is primarily collected under real-life situations and often available more quickly to monitoring teams, according to Kristin Mauri, Director of Solution Services, Remarque Systems.
Researchers with the University of Cambridge for the first time leveraged human data to quantify the speed of various processes in the brain that lead to Alzheimer’s disease.
